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Abstract
Background: Colorectal cancer is one of the most common cancers and causes of cancer-related death. Up to approximately
70% of patients with metastatic colorectal cancer (mCRC) have metastases to the liver at initial diagnosis. Second-line systemic
treatment in mCRC can prolong survival after development of disease progression during or after first-line treatment and in those
who are intolerant to first-line treatment.
Objective: The objective of this study is to evaluate the efficacy and safety of transarterial radioembolization (TARE) with
TheraSphere yttrium-90 (90Y) glass microspheres combined with second-line therapy in patients with mCRC of the liver who
had disease progression during or after first-line chemotherapy.
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Methods: EPOCH is an open-label, prospective, multicenter, randomized, phase 3 trial being conducted at up to 100 sites in
the United States, Canada, Europe, and Asia. Eligible patients have mCRC of the liver and disease progression after first-line
chemotherapy with either an oxaliplatin-based or irinotecan-based regimen and are eligible for second-line chemotherapy with
the alternate regimen. Patients were randomized 1:1 to the TARE group (chemotherapy with TARE in place of the second
chemotherapy infusion and subsequent resumption of chemotherapy) or the control group (chemotherapy alone). The addition
of targeted agents is permitted. The primary end points are progression-free survival and hepatic progression-free survival. The
study objective will be considered achieved if at least one primary end point is statistically significant. Secondary end points are
overall survival, time to symptomatic progression defined as Eastern Cooperative Oncology Group Performance Status score of
2 or higher, objective response rate, disease control rate, quality-of-life assessment by the Functional Assessment of Cancer
Therapy-Colorectal Cancer questionnaire, and adverse events. The study is an adaptive trial, comprising a group sequential design
with 2 interim analyses with a planned maximum of 420 patients. The study is designed to detect a 2.5-month increase in median
progression-free survival, from 6 months in the control group to 8.5 months in the TARE group (hazard ratio [HR] 0.71), and a
3.5-month increase in median hepatic progression-free survival time, from 6.5 months in the control group to 10 months in the
TARE group (HR 0.65). On the basis of simulations, the power to detect the target difference in either progression-free survival
or hepatic progression-free survival is >90%, and the power to detect the target difference in each end point alone is >80%.
Results: Patient enrollment ended in October 2018. The first interim analysis in June 2018 resulted in continuation of the study
without any changes.
Conclusions: The EPOCH study may contribute toward the establishment of the role of combination therapy with TARE and
oxaliplatin- or irinotecan-based chemotherapy in the second-line treatment of mCRC of the liver.
Trial Registration: ClinicalTrials.gov NCT01483027; https://clinicaltrials.gov/ct2/show/NCT01483027 (Archived by WebCite
at http://www.webcitation.org/734A6PAYW)
International Registered Report Identifier (IRRID): RR1-10.2196/11545
(JMIR Res Protoc 2018;8(1):e11545)   doi:10.2196/11545
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Introduction
Colorectal cancer is the third most common newly diagnosed
cancer and the fourth most common cause of cancer death
globally [1]. Metastatic disease is observed at first diagnosis in
an estimated 25% of new patients (synchronous distant
metastasis) [2] and eventually develops in a further estimated
60% of patients (metachronous metastasis) [2-4]. The prognosis
for metastatic colorectal cancer (mCRC) remains poor, with a
5-year survival rate around 14% [5]; the 5-year relative survival
is worse for patients with metachronous metastasis than for
those with synchronous metastasis (17.6% vs 7.2%) [6]. The
liver is the most common site of metastasis because the blood
that drains from the bowel and colon goes through the portal
vein, and the circulating tumor cells are deposited in the liver
[7,8]. Up to approximately 70% of metastatic patients present
with mCRC to the liver at the initial diagnosis [7].
Although the outcome for patients with mCRC has improved
with the rapid progress in diagnostic techniques and treatments,
for most patients with mCRC, treatment is palliative rather than
curative because the majority of patients are not candidates for
surgical resection [9]. In mCRC patients for whom cure is not
possible, potential goals of treatment are to prolong
progression-free intervals, prolong life, improve quality of life,
palliate symptoms, shrink tumor size, and protect the normal
liver parenchyma. Patients with mCRC to the liver can achieve
a median overall survival of approximately 30 months [10,11].
Most patients with mCRC receive systemic chemotherapy with
or without targeted biological agents. First- and second-line
systemic therapies typically include a fluoropyrimidine
combined with either irinotecan (FOLFIRI regimen) or
oxaliplatin (FOLFOX regimen). Biologically targeted agents
include vascular endothelial growth factor inhibitors and
epidermal growth factor receptor inhibitors [12]. Liver-directed
therapies, that is, transarterial chemoembolization (TACE) and
transarterial radioembolization (TARE), are well established in
the armamentarium for treatment of metastatic disease, mostly
in the salvage setting. The delivery of chemotherapy or
radioactive-labeled yttrium-90 (90Y) microspheres via the
hepatic arteries is selective to liver tumors because liver tumors
are mostly perfused via the hepatic arteries, whereas normal
hepatic parenchyma receives blood from the portal venous
system [13].
Most mCRC patients who receive standard first-line treatment
with combination regimens and treatment with targeted
biological agents eventually develop either intolerance,
recurrence, or progression and require second-line treatment.
TARE is a treatment option that could be considered for patients
with unresectable colorectal cancer and liver-dominant
metastases who are refractory to chemotherapy. In such patients,
prospective and retrospective studies have demonstrated that
TARE is feasible and may compare favorably with
standard-of-care treatment [14-16]. A rationale for the
combination of TARE and systemic therapy is that liver-directed
treatment with TARE will better control liver disease and
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systemic therapy will control extrahepatic progression and
micrometastatic disease.
Here, we report the design of the EPOCH study: A Phase 3
Randomized Clinical Trial Evaluating TheraSphere in Patients
with Metastatic Colorectal Carcinoma of the Liver Who Have
Failed First-line Chemotherapy (trial registration:
clinicaltrials.gov NCT01483027). The EPOCH study is being
conducted to evaluate progression-free survival and hepatic
progression-free survival in patients with mCRC when
TheraSphere is added to second-line standard-of-care
chemotherapy. In the second-line mCRC treatment setting, the
EPOCH study is expected to be the largest study of the
comparison of locoregional therapy with TARE in combination
with standard-of-care systemic therapy versus standard-of-care
systemic therapy alone.
Methods
Overview of Design
The study is being conducted in accordance with the Declaration
of Helsinki. Participating institutions obtained institutional
review board approval of the protocol and informed consent
form and are responsible for obtaining written informed consent
from patients at screening (Multimedia Appendix 1).
EPOCH is an ongoing, open-label, prospective, multicenter,
randomized, phase 3 clinical trial. The objective is to evaluate
the efficacy and safety of TARE with TheraSphere in patients
with mCRC of the liver who have disease progression on
first-line chemotherapy with either an oxaliplatin-based regimen
or an irinotecan-based regimen and who are eligible for
second-line chemotherapy with the alternate regimen. All
patients receive chemotherapy; however, in the TARE group,
TheraSphere is administered in place of the second cycle of
chemotherapy, with chemotherapy subsequently resuming. A
maximum of 420 patients are planned to be randomized at up
to 100 sites in the United States, Canada, Europe, and Asia. The
2 primary end points are progression-free survival and hepatic
progression-free survival. The study objective will be considered
achieved if at least one primary end point is statistically
significant. All patients are to be followed prospectively from
randomization to death until the predefined number of
progression-free survival events, to allow the final analysis to
be conducted, have occurred.
The study commenced enrollment with a single primary end
point of progression-free survival, with hepatic progression-free
survival as a secondary end point. Progression-free survival is
a valid surrogate end point for overall survival for mCRC
patients receiving first- and second-line systemic chemotherapy
with or without the inclusion of systemic targeted therapies
[17,18]. The expected benefit for patients receiving a
liver-directed therapy is an increased duration of liver disease
control. Accordingly, the efficacy of a liver-directed treatment
can be evaluated and measured by hepatic progression-free
survival. A survival benefit of liver-directed treatment could
occur via improvement of hepatic progression-free survival.
Other liver-directed therapies, such as intra-arterial
chemotherapy infusion, radiofrequency ablation, or TACE with
drug-eluting beads, have demonstrated improvement of overall
survival through improved control of hepatic disease [19,20];
thus, the efficacy of a liver-directed treatment may be evaluated
and measured by hepatic progression-free survival [21]. To
demonstrate the clinical benefit of TARE in mCRC patients
with liver metastases, hepatic progression-free survival was
subsequently included as a second primary end point.
Progression-free survival and hepatic progression-free survival
will evaluate the 2 major determinants of progression
(extrahepatic factors and intrahepatic factors).
Trained clinical research associates performed a site initiation
visit with investigators and their teams before the start of patient
screening. Patient medical records are reviewed in a timely
manner to confirm eligibility and compliance with the study
protocol. Data entries on the electronic case report forms are
reviewed by the clinical research associate and compared with
the medical records and study protocol on an ongoing basis. An
independent data monitoring committee (IDMC) was established
to oversee the conduct of the study. The IDMC met periodically
to review enrollment, protocol deviations, and safety events. In
addition, the IDMC conducted and reviewed an initial feasibility
safety analysis and will evaluate the progression-free survival
data at interim analyses for consideration of stopping the study
early for efficacy. The IDMC was tasked to make formal
recommendations to the study sponsor based on decision rules
in the IDMC charter.
Screening and Eligibility
Screening and baseline evaluations occur from day −14 to day
0, where day 0 is the day of randomization. Demographics,
medical history, medications, prior treatment history, and
Eastern Cooperative Oncology Group (ECOG) Performance
Status score were documented. Patients undergo physical
examination and have baseline clinical laboratory tests including
blood chemistry, hematology, coagulation tests, and colorectal
cancer tumor marker (serum carcinoembryonic antigen). Kirsten
retrovirus-associated DNA sequence (KRAS) oncogene status
is determined if it is not already known. Serum pregnancy tests
were conducted for women of childbearing potential. Patients
must have baseline images for disease evaluation (spiral
computerized tomography [CT] or magnetic resonance imaging
[MRI] of the abdomen, pelvis, and chest) taken within 28 days
before day 0 (randomization) when first-line chemotherapy is
completed or after, and images must show measurable target
tumors in the liver according to Response Evaluation Criteria
In Solid Tumors (RECIST) version 1.1 [22]. Tumor burden was
estimated from CT scans (visual or volumetric assessment).
Inclusion and exclusion criteria are shown in Textbox 1.
Eligible patients must discontinue first-line chemotherapy and
biologic agents during screening for a washout period of at least
14 days. The intended second-line chemotherapy regimen,
including any biological agents, and dosages are decided.
Patients complete the Functional Assessment of Cancer
Therapy-Colorectal Cancer (FACT-C) quality-of-life
questionnaire during the screening period.
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Textbox 1. Inclusion and exclusion criteria for the EPOCH study.
Inclusion criteria
• Age at least 18 years.
• Colorectal cancer with unresectable metastatic unilobar or bilobar liver disease and disease progression in the liver with either (1) oxaliplatin-based
or (2) irinotecan-based first-line chemotherapy; patient must be eligible to receive second-line standard-of-care chemotherapy with the alternate
regimen. The determination of unresectable was based on local consideration, provided that the treatment decision was made by a multidisciplinary
team that included a surgeon.
• Primary tumor either resected or clinically stable.
• Baseline images with measurable target tumors in the liver according to Response Evaluation Criteria in Solid Tumors version 1.1 using standard
imaging techniques taken within 28 days before randomization. Images must be taken at completion of first-line chemotherapy or after.
• Tumor replacement less than 50% of total liver volume.
• Eastern Cooperative Oncology Group Performance Status score of 0 to 1 from screening to first treatment on study.
• Laboratory parameters: serum creatinine up to 2.0 mg/dL, serum bilirubin up to 1.2× upper limit of normal, albumin at least 3.0 g/dL, and
neutrophil count more than 1200/mm3 (1.2 × 109/L).
Exclusion criteria
• Prior external beam radiation treatment to the liver and prior intra-arterial liver-directed therapy (including transarterial chemoembolization or
TheraSphere yttrium-90 microspheres therapy).
• Planned nonstudy liver-directed therapy or radiation therapy. Planned treatment with biological agents within 28 days before receiving TheraSphere.
• Confirmed extrahepatic metastases. Limited, indeterminate extrahepatic lesions in the lung and/or lymph nodes are permitted (up to 5 lesions in
the lung, with each individual lesion smaller than 1 cm; any number of lymph nodes with each individual node smaller than 1.5 cm).
• History of hepatic encephalopathy; history of severe peripheral allergy or intolerance to contrast agents, narcotics, sedatives, or atropine that
cannot be managed medically.
• Contraindications to angiography and selective visceral catheterization, such as bleeding diathesis or coagulopathy that is not correctable by usual
therapy with hemostatic agents; contraindications to the planned second-line chemotherapy regimen.
• Pulmonary insufficiency or clinically evident chronic obstructive pulmonary disease.
• Cirrhosis or portal hypertension.
• Receipt of intervention for the Ampulla of Vater or compromise thereof.
• Clinically evident ascites aside from trace ascites on imaging.
• Unresolved toxicities related to cancer therapy that the investigator determines will continue and compromise patient safety.
• Significant life-threatening extrahepatic disease, for example, unresolved diarrhea or serious unresolved infections, such as human immunodeficiency
virus, acute hepatitis B virus, or hepatitis C virus.
Randomization and Stratification
Eligible patients are randomized on day 0 in a 1:1 ratio to either
the control group or the TARE group. If the study is not stopped
early for efficacy, approximately 210 patients will be
randomized to each group. To randomize eligible patients, the
study site contacts the central randomization office where
randomization will be determined using assignment by a
computer-generated randomization scheme. Upon
randomization, each patient is assigned an identity code. To
ensure that treatment groups are balanced, patients are stratified
at randomization based on the extent of liver involvement
(unilobar vs bilobar disease), type of first-line chemotherapy
(oxaliplatin-based vs irinotecan-based), and KRAS status (wild
type vs mutant). Additional factors permitting covariate analysis
are captured at randomization but are not stratification criteria.
These factors have been defined based on the planned covariate
analyses. Patients randomized to either the control or the TARE
group who are unable to receive their planned study treatment
continue to be followed under their assigned study group for
the purpose of the intent-to-treat analysis.
Chemotherapy
The treatment schema is shown in Figure 1.
For both groups, second-line chemotherapy started within 21
days of randomization. If during the first-line chemotherapy,
patients had received an oxaliplatin-based regimen, then during
the EPOCH study, they receive a standard-of-care
irinotecan-based chemotherapy. Those who received an
irinotecan-based regimen as first-line therapy receive a
standard-of-care oxaliplatin-based regimen in this study.
Generally, second-line chemotherapy is given every 2 weeks
for 6 to 12 cycles; chemotherapy is continued at the
investigator’s discretion.
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Figure 1. Clinical trial schema for the TheraSphere microspheres EPOCH study. Eligible patients have a washout period of at least 14 days from
previous chemotherapy and biologic agents. Second-line chemotherapy is started within 21 days of randomization. Control group: biologic agents are
permitted starting at the first cycle of second-line chemotherapy. TARE group: biological agents are discontinued at least 28 days before TARE and are
not permitted until the first cycle of second-line chemotherapy that occurs after TARE. HPFS: hepatic progression-free survival; PFS: progression-free
survival; TARE: transarterial radioembolization with TheraSpheres™ microspheres.
Control group patients can receive biological agents starting
with the first cycle of second-line chemotherapy. For the TARE
group, one cycle of chemotherapy is administered before the
TheraSphere treatment, and biological agents may only be added
to the first cycle of chemotherapy regimen that occurs after the
TheraSphere administration.
Transarterial Radioembolization
In the TARE group, TheraSphere microspheres are administered
in place of the second cycle of chemotherapy. The treatment
approach for TheraSphere can be lobar or selective. Patients
with unilobar disease receive TARE to the diseased lobe.
Patients with bilobar disease receive treatment to both lobes via
successive lobar infusions during the same treatment session.
Biological agents must be discontinued for at least 28 days
before TARE. Chemotherapy resumes 2 weeks after TARE, at
which time treatment with biologic agents may be started.
Eligibility for TARE with TheraSphere microspheres is
determined by evaluations that include a pretreatment
angiography with technetium-99m macroaggregated albumin
(99mTc-MAA), followed by a99mTc-MAA single-photon emission
computed tomography (SPECT) or SPECT-CT scan to assess
the potential for shunting microspheres to the lungs as well as
the potential for the deposition of microspheres to the
gastrointestinal tract. Repeat99mTc-MAA may be needed for
subsequent treatments to estimate cumulative lung shunt or to
reassess gastrointestinal shunting. Patients are ineligible for
TARE if radiation exposure to the lungs exceeds 30 Gy (or 50
Gy cumulative across all planned infusions, estimated during
the dose calculation) or embolization cannot be performed to
effectively block gastrointestinal blood flow from the hepatic
arterial system. Randomized patients deemed ineligible for
TARE continue with the planned second-line chemotherapy.
Radioembolization can be performed via a segmental or lobar
approach, depending on operator preference and angiographic
anatomy. The targeted administered dose is 120±10% Gy to the
target volume, based on a single-compartment Medical Internal
Radiation Dose model [23].
TheraSphere should be administered by appropriately trained
or designated personnel from the departments of radiology,
nuclear medicine, and/or interventional radiology. Before the
activation of trial sites with the appropriate approvals to
administer TheraSphere, the health care professionals directly
involved in the planning and administration of TheraSphere are
required to attend a center of excellence training in which expert
speakers lecture on topics related to patient selection and
TheraSphere dosimetry and administration. Investigational
teams must then accomplish at least three (or five) patient
treatment cases with TheraSphere. The minimum number of
cases is determined by a trained team of study sponsor proctors
who review the treatment planning and perform on-site review
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of treatment administration. Upon completion of the training
program, investigators are trained on the study protocol.
Treatment for Disease Progression
After disease progression is observed and confirmed, patients
in either group may receive the best alternative therapy or care
that the investigator considers appropriate. Patients in the TARE
group who have hepatic progression with hepatic lesions that
are still amenable to TheraSphere are eligible for repeat
treatment with TheraSphere. In these patients, TheraSphere may
be administered at the investigator’s discretion on separate
treatment days. Although this is not a cross-over study, patients
in the control group who have hepatic progression with hepatic
lesions that are amenable to liver-directed therapy can receive
TheraSphere or any other liver-directed therapies according to
the investigator’s decision. As with the initial administration of
TheraSphere, biological agents must be discontinued for at least
28 days before any additional TheraSphere administration.
Follow-Up Evaluations
The schedule of postrandomization evaluations is shown in
Table 1.
Efficacy assessment scans are taken according to
standard-of-care clinical management guidelines every 8 weeks
(±1 week) after randomization until either death, withdrawal
from study follow-up, or end of the study. The imaging modality
used at baseline must be used throughout the study. Image
assessment must follow study imaging guidelines. Tumor
response is evaluated locally according to RECIST version 1.1.
In case of progression, a confirmatory scan is requested. If the
first progression occurs outside the liver, efforts must be made
to continue the scheduled follow-up until hepatic progression
occurs; no confirmatory scan is requested. Imaging performed
for disease assessment must be submitted to the sponsor or
designate for centralized review. Adverse events, serious adverse
events, and unanticipated adverse device effects, as defined by
the study protocol, will be collected throughout the study.
Independent review of the CT and MRI images is performed
by a central imaging review organization. Central image review
interpretation (independent reads by 2 radiologists with
adjudication, if required, by a third radiologist) is performed in
a blinded fashion on the full set of patient images and captured
on an electronic case report form. The results of the primary
study end points will be based on the central image review
findings.
Efficacy End Points and Definitions
The primary efficacy end points of the EPOCH study are
progression-free survival and hepatic progression-free survival.
The secondary efficacy end points are overall survival, time to
symptomatic progression, objective response rate, disease
control rate, quality of life assessment by FACT-C questionnaire,
and adverse events. Definitions of these outcomes are as follows:
1. Progression-free survival is the time from the randomization
date to the date of radiological progression or death from
any cause, whichever occurs first. Radiological progression
is determined by blinded central image review according
to RECIST version 1.1.
2. Hepatic progression-free survival is the time from
randomization to the date of radiological progression in the
liver or death from any cause, whichever occurs first.
Radiological progression is determined by blinded central
image review according to RECIST version 1.1.
3. Overall survival is the time from the randomization date to
death from any cause.
4. Time to symptomatic progression is the time from
randomization to ECOG Performance Status score greater
than 2 points. Such deterioration in performance score is
to be confirmed at one subsequent evaluation at least 8
weeks later.
5. Objective response rate is the proportion of patients
achieving a best tumor response of either complete response
or partial response during the study, as assessed by blinded
central image review according to RECIST version 1.1.
6. Disease control rate is the proportion of patients achieving
a best tumor response of either complete response, partial
response, or stable disease during the study, as assessed by
blinded central image review according to RECIST version
1.1.
7. Quality-of-life assessment is based on the patient-reported
FACT-C questionnaire. Deterioration in quality of life is a
decline of at least seven points in the total FACT-C score
or death, whichever occurs first. The time to deterioration
in quality of life is calculated as the time from
randomization to deterioration in quality of life.
TARE can cause tumor inflammation (edema) early after
treatment; therefore, any tumor assessments performed within
six weeks of randomization will not be included in the analysis
of imaging-related efficacy end points to rule out the risk of
false progression.
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Table 1. Schedule of events after randomization on day 0.
Study visits until
death or end of study
Additional TARE
workup and administra-
tionb
Study visits to
progression
First TAREa workup
and administration
in TARE group
ChemotherapyInterventions and assessments
Every 8 weeks (±1
week)
After hepatic progres-
sion, TARE replaces a
cycle of chemotherapy
Every 8 weeks
from day 0 (±1
week)
Replaces second cy-
cle of chemotherapy
Every 2 weeksDescription
Interventions
—✓—✓—eHepatic angiogram,99mTc-MAAc
scan,d calculate liver volume and
mass,d calculate TheraSphere
dose,d order and administer
TheraSphere
————✓Administer second-line
chemotherapy
Assessments
✓g✓✓✓✓gECOGf Performance Status
—✓✓—✓Hematologyh, chemistry panel,
liver function tests
—✓——✓jCoagulation testsi
—✓—✓—Serum pregnancyk
——✓——Tumor markers for colorectal can-
cer (serum carcinoembryonic anti-
gen)
✓————Record and administer any
chemotherapy following second-
line chemotherapyl
✓g—✓——Quality-of-life questionnaire
—✓✓——Spiral CTm or MRIn of the ab-
domen, pelvis, or chesto
✓✓✓✓✓Assess and report adverse events
✓✓✓✓✓Review and record concurrent
medication
✓————Final end point, efficacy and safety
documentation, and exit patient
aTARE: transarterial radioembolization.
bIn lesions amenable to further TARE.
c99mTc-MAA: technetium-99m macroaggregated albumin.
dBefore TARE administration.
eAssessment or intervention was not conducted at that time.
fECOG: Eastern Cooperative Oncology Group.
gCan be done remotely if patient is not coming in for clinic visit.
hHematology tests: white blood cells with differential, hemoglobin, hematocrit, and platelets.
iCoagulation tests: prothrombin time, partial thromboplastin time, and international normalized ratio.
jOnly required at chemotherapy visits as clinically indicated, that is, if patient is being followed for coagulopathy.
kRequired for female patients of childbearing potential.
lAll randomized patients must receive chemotherapy within 21 days of randomization.
mCT: computed tomography.
nMRI: magnetic resonance imaging.
oAll attempts should be made to obtain imaging every 8 weeks until hepatic progression, plus confirmatory scan.
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The following additional efficacy variables will be assessed:
• Progression-free survival and hepatic progression-free
survival by investigator assessment, with progression
determined by the investigator according to RECIST version
1.1.
• Objective response rate, determined by the investigator,
defined as the proportion of randomized patients achieving
a best overall response of complete response or partial
response, as defined by RECIST version 1.1.
• Duration of objective response will be determined for
patients who had a best response of complete response or
partial response. Duration of objective response is defined
as the time from the first date of complete response or
partial response to date of progression or death from any
cause, whichever occurs first. Duration of response will be
assessed separately for response determined by blinded
central image review and by investigator assessment.
• Disease control rate, as determined by the investigator,
defined as the proportion of randomized patients achieving
a best overall response of complete response, partial
response, or stable disease as defined by RECIST version
1.1.
• Duration of disease control will be determined for patients
who had a best response of complete response, partial
response, or stable disease. Duration of disease control is
defined as the time from the first date of complete response,
partial response, or stable disease until the date of
progression or death from any cause, whichever occurred
first. Duration of disease control will be assessed separately
for response determined by blinded central image review
and by investigator assessment.
• Depth of response, defined as the percentage change from
baseline to the nadir in the sum of the longest diameters of
target lesions.
• Posttreatment tumor shrinkage, defined as the proportion
of patients achieving a decrease of at least 20% in the sum
of the longest diameters of target lesions.
• Change from baseline in tumor marker for colorectal cancer
(carcinoembryonic antigen).
Planned Statistical Analysis
Sample Size Estimate
The study is a phase 3 adaptive trial, comprising a group
sequential design with 2 interim analyses. The study could be
stopped early for efficacy at an interim analysis based on
superiority in progression-free survival but not hepatic
progression-free survival.
The study is designed to detect a 2.5-month increase in median
progression-free survival, from 6 months in the control group
to 8.5 months in the TARE group (hazard ratio [HR] 0.71), and
a 3.5-month increase in median hepatic progression-free survival
time, from 6.5 months in the control group to 10 months in the
TARE group (HR 0.65). On the basis of simulations, the power
to detect the target difference in either progression-free survival
or hepatic progression-free survival is >90%, and the power to
detect the target difference in each end point alone is >80%,
using log-rank tests.
The analysis of progression-free survival will be based on a
group sequential design with 2 interim analyses at 50% and
70% of the required total number of 344 progression-free
survival events with a stopping boundary defined by the rho
family error spending function with ρ=1.5 [24]. It is estimated
that a maximum of 420 patients will need to be recruited over
36 months, with a 1-year additional follow-up period, allowing
for 10% of patients lost to follow-up and for whom a date of
progression or death is not recorded. Although the forecasted
accrual period has been increased to 60 months, this does not
increase the number of patients required or affect the statistical
power of the study because both the power and the timing of
the interim and final analyses are based on the number of
progression-free survival events rather than the number of
patients. The Hochberg procedure will be used to control type
1 error for the 2 primary end points at the final analysis [25].
A simulation study, assuming that progression-free survival and
hepatic progression-free survival have a correlation between
0.3 and 0.8, showed that the power to detect the target difference
in either median progression-free survival (ie, HR 0.71) or
median hepatic progression-free survival (ie, HR 0.65) is >90%,
and the power to detect the target difference in progression-free
survival or hepatic progression-free survival alone is >80%.
The simulation study also demonstrated control of type 1 error
at the nominal one-sided level of 0.025.
Populations
The intent-to-treat population will comprise all randomized
patients. The per-protocol population will be analyzed according
to the treatment actually received, excluding patients with major
protocol deviations that may affect the efficacy evaluation. The
safety analysis population will comprise all randomized patients
who received study treatments at least once.
Primary Efficacy End Points
Analysis of Primary End Points
Progression-free survival and hepatic progression-free survival
will be compared between the control and TARE groups using
log-rank tests. The HR and 2-sided 95% CI will be computed.
Kaplan-Meier curves will also be produced.
Interim Analyses of Primary End Point of Progression-Free
Survival
The first interim analysis is planned at 172 progression-free
survival events. Progression-free survival will be compared
between treatment groups using a log-rank test converted to a
z-score and compared with the nominal critical value of 2.372
based on the rho family error spending function corresponding
to a one-sided P ≤.0088, allowing the study to be stopped early
for efficacy, in which case hepatic progression-free survival
will be tested at the same boundary as progression-free survival
using a log-rank test converted to a z-score.
A second interim analysis is planned at 241 progression-free
survival events, where progression-free survival will be
compared between treatment groups using a log-rank test
converted to a z-score and compared with the nominal critical
value of 2.330 based on the rho family error spending function
corresponding to a one-sided P ≤.0099, allowing the study to
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be stopped early for efficacy. If the study is stopped early for
progression-free survival at the second interim analysis, hepatic
progression-free survival will be tested using the boundary
derived based on an incremental alpha of .0057. This boundary
will account for the correlation between the z-score for
progression-free survival at the first interim analysis and the
z-score for hepatic progression-free survival at the second
interim analysis, which is determined by the observed number
of hepatic progression-free survival events at the first interim
analysis and the cumulative number of hepatic progression-free
survival events observed at the second interim analysis.
Final Analysis of Primary End Points of Progression-Free
Survival and Hepatic Progression-Free Survival
The final analysis is planned at 344 progression-free survival
events. The Hochberg procedure will be used to control type 1
error for the 2 primary end points [25]. Whichever of
progression-free survival or hepatic progression-free survival
that has the larger P value will be compared between treatment
groups using a log-rank test converted to a z-score and compared
with the nominal critical value of 2.312 with a corresponding
one-sided P ≤.0104 required to declare a statistically significant
improvement in hazard rate for this end point. To ensure that
type 1 error is controlled for both primary end points, this
boundary is based on the incremental alpha of .0104 instead of
the P value scale boundary of .0168, using the rho family error
spending function with ρ=1.5.
According to the Hochberg procedure, if the primary end point
with the larger P value is statistically significant, then the other
primary end point is also statistically significant. However, if
the primary end point with the larger P value is not statistically
significant, then the other primary end point will be compared
between treatment arms using a log-rank test converted to a
z-score and compared with the nominal critical value of 2.562
based on the rho family error spending function, with a
corresponding one-sided P ≤.0104/2=.0052 required to declare
a statistically significant improvement in hazard rate for this
end point.
Analysis of Secondary Efficacy End Points
Comparison between treatment groups for all secondary end
points will be conducted at the final analysis at one-sided alpha
of .025.
Time-to-event end points (ie, overall survival, time to
symptomatic progression, and time to deterioration in quality
of life) will be compared between treatment groups using a
log-rank test. Disease control rates and objective response rate
will be compared between treatment groups using the
continuity-adjusted Newcombe-Wilson test. The FACT-C score
will be compared between treatment arms using a mixed linear
model with baseline score and the relative time from baseline
as covariates.
Poolability and Other Analyses
Univariable Cox regression analyses of the primary efficacy
end points and all other time-to-event end points (ie, overall
survival, time to symptomatic progression, and time to
deterioration in quality of life) will be conducted with the
following baseline factors, one at a time, together with
randomized group: age group, race, ethnicity, gender, unilobar
versus bilobar disease, oxaliplatin or irinotecan first-line
chemotherapy, KRAS status, ECOG performance status, region,
duration of time from date of diagnosis of mCRC to
randomization, duration of time from the start of first-line
chemotherapy to date of progression on first-line therapy,
duration of time from date of progression on first-line therapy
to date of start of second-line chemotherapy, synchronous versus
metachronous metastases, location of primary tumor at the time
of first diagnosis of primary colorectal cancer (right-sided vs
left-sided), tumor burden, and presence of lung or lymph node
lesions. Receipt of oxaliplatin- or irinotecan-based second-line
chemotherapy and the receipt of biological agents during the
study will also be assessed one at a time. This will allow an
assessment of each of these factors on the study outcomes.
To assess the poolability of data across study sites, multivariable
Cox regression analyses of the time-to-event end points will be
conducted, including factors of randomized group, study site,
randomized group by study site interaction, and the factors from
the univariable analyses that have a one-sided P<.075. Similarly,
to assess the poolability of data across regions, Cox regression
analysis will be conducted with study site replaced by region.
Logistic regression analyses of the binary end points (ie,
objective response rate and disease control rate) will be
conducted in the same way as the Cox regression analyses
described above.
Results
After the first 20 patients in the TARE group received
TheraSphere microspheres followed by at least two cycles of
chemotherapy, a feasibility safety assessment was conducted.
The IDMC reviewed the safety results of both groups in an
unblinded fashion. A consideration for adjusting the dose of
cytotoxic agents, other safety recommendations, or stopping
further enrollment could have been made if there was either an
unanticipated patient death definitely or probably related to the
sequential administration of TARE with oxaliplatin-based or
irinotecan-based chemotherapy or there was a pattern of serious
toxicity clearly related to the sequential administration of TARE
with oxaliplatin-based or irinotecan-based chemotherapy.
However, the IDMC did not recommend any changes to the
study.
Enrollment for the study completed in October 2018. Results
of the first interim analysis were reviewed by the IDMC, and
their recommendation was to continue the study without any
changes.
Discussion
Overview
First-line chemotherapy regimens for unresectable mCRC are
well established [10]. Second-line therapy using the combination
of chemotherapy and targeted therapies has demonstrated
efﬁcacy with improved overall survival, progression-free
survival, and overall response rate in comparison with
chemotherapy alone [26,27]. However, the choice of the optimal
treatment strategy remains challenging and is mostly driven by
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the type of and response to the first-line treatment administered,
the type of retrovirus-associated DNA sequence mutation
(KRAS, NRAS, and HRAS), microsatellite stability, tumor
burden, patient performance status, and comorbidities.
The EPOCH study was designed to account for known
prognostic and predictive factors [10]. Patients in the EPOCH
study are stratified at randomization according to key factors
that could influence the primary or secondary study end points:
(1) tumor load (unilobar vs bilobar), (2) KRAS status (wild type
vs mutant), and (3) prior first-line chemotherapy
(oxaliplatin-based or irinotecan-based) to ensure balance
between groups.
High tumor load is a known factor of chemotherapy failure [28].
KRAS mutation is a predictive factor of nonresponse to
epidermal growth factor receptor inhibitor treatment [29,30].
Whether KRAS mutation is a prognostic factor is widely
debated. KRAS mutant patients may have different sensitivity
to treatment compared with KRAS wild-type patients [31-35],
and KRAS mutational status will drive the postprogression
treatment received. Second-line treatment with irinotecan-based
regimens has been associated with shorter median
progression-free survival [36]. Tumor sidedness is currently
undergoing intense study, given the recognition that tumor
location is prognostic and predictive [37-39]. Tumor sidedness
is not a stratification factor in the EPOCH study because when
the study was designed, the importance of this prognostic factor
was less understood; however, a preplanned analysis to assess
the impact of this factor will be performed. In addition, the
impact of important covariates, such as asynchronous or
metachronous metastases, location of primary tumors (right vs
left), presence of lung or lymph node lesions at baseline, and
biological agents received, will be assessed. This study was
designed before well-established data on the prognostic
significance of BRAF mutations were available, and thus, BRAF
mutation status was not collected on the electronic case report
forms. However, because BRAF mutant tumors are often right
sided, the preplanned analysis to assess the impact of right-sided
vs left-sided primary tumor location should provide an indirect
assessment of BRAF mutation status.
TARE treatment for patients with liver or liver-dominant disease
has been outlined in prospective and retrospective studies that
have demonstrated that this option was manageable in this
patient population and compared favorably with standard-of-care
treatment [14-16,40,41]. The relevancy of TARE in the first-line
setting was extensively explored in the pooled analyses of the
randomized studies FOXFIRE, SIRFLOX, and
FOXFIRE-Global [42,43]. This analysis demonstrated that
TARE (with 90Y resin microspheres) in association with an
oxaliplatin- and fluorouracil-based chemotherapy regimen failed
to improve overall survival and progression-free survival
compared with chemotherapy alone. However, the combination
of TARE with first-line oxaliplatin-based chemotherapy
significantly improved response rate and liver-specific
progression-free survival in comparison with chemotherapy
alone. In spite of an increased toxicity in the TARE group, the
quality of life was not significantly different between the 2
treatment groups [42-44]. Factors that may have contributed to
the failure of the previous 90Y resin microspheres trials are a
long delay between randomization to starting TARE treatment,
the percentage of patients with extrahepatic metastatic disease
at baseline (40% of patients enrolled), the lower percentage of
patients in the TARE group who received postprogression
therapies, and inferior chemotherapy dose intensity in the TARE
group.
In the EPOCH study, the patient population and treatment
schedule were selected to avoid these factors that may have
contributed to the failure of the previous first-line trials. Patients
with rapid and diffuse progression of disease and those with
extrahepatic metastasis are not eligible to participate, thus
limiting the risk of the trial not reaching a primary
progression-free survival end point because of extrahepatic
progression. In addition, to avoid a discrepancy between the 2
treatment groups regarding chemotherapy intensity and the
delay to start the attributed treatment, the 2 groups must start
the first study treatment, that is, chemotherapy, within 21 days
after randomization. Both groups also receive an optimal dose
of chemotherapy based on oncologist determination. No dose
reduction was preplanned in the TARE group. The safety of the
treatment schedule was evaluated after the treatment of 20
patients, and the schedule was considered safe by the IDMC.
Limitations of the study include the unblinded design, which is
required for such a complex treatment intervention when it
would be unethical to consider a sham procedure for the control
group.
Conclusion
It is important to establish an effective and tolerable treatment
to improve patient outcome for unresectable liver metastases
from colorectal cancer. One challenge in the treatment of mCRC
patients with liver-dominant disease is providing an efficient
treatment of the cancer without impairing liver function and
allowing systemic treatment to continue with minimal
interruption. TARE has a limited toxicity profile when used
appropriately and, consequently, a low impact on the dose
intensity and duration of systemic treatment. Enrollment for the
EPOCH study completed in October 2018. Data from this trial
will enhance the knowledge base regarding optimal treatment
options for patients with unresectable mCRC.
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90Y: yttrium-90
99mTc-MAA: technetium-99m macroaggregated albumin
CT: computerized tomography
ECOG: Eastern Cooperative Oncology Group
EPOCH: A Phase 3 Clinical Trial Evaluating TheraSphere in Patients with Metastatic Colorectal Carcinoma of
the Liver who have Failed First Line Chemotherapy
FACT-C: Functional Assessment of Cancer Therapy-Colorectal Cancer
HR: hazard ratio
IDMC: independent data monitoring committee
KRAS: Kirsten retrovirus–associated DNA sequence
mCRC: metastatic colorectal cancer
MRI: magnetic resonance imaging
RECIST: Response Evaluation Criteria in Solid Tumors
SPECT: single-photon emission computed tomography
TACE: transarterial chemoembolization
TARE: transarterial radioembolization
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